证券代码：688180 证券简称：君实生物 公告编号：临 2025-040 上海君实生物医药科技股份有限公司 2025 年半年度募集资金存放与实际使用情况专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据中国证券监督管理委员会（以下简称"中国证监会"）《上市公司募集 资金监管规则》《上海证券交易所科创板上市公司自律监管指引第1号——规范 运作》和《上海证券交易所科创板股票上市规则》等相关规定，上海君实生物医 药科技股份有限公司（以下简称"公司"）董事会将公司2025年半年度（以下简 称"报告期"）募集资金存放与实际使用情况专项说明如下： 根据中国证监会于2020年5月20日出具的《关于同意上海君实生物医药科技 股份有限公司首次公开发行股票注册的批复》（证监许可〔2020〕940号），公 司获准向社会公开发行人民币普通股87,130,000股，每股发行价格为人民币55.50 元，募集资金总额为人民币4,835,715,000.00元；扣除不含税发行费用人民币 338,736,673.27元，实际募集资金净额为人民 ...

证券代码：688180 证券简称：君实生物 公告编号：临 2025-041 上海君实生物医药科技股份有限公司 关于变更注册资本、取消监事会并修订《公司章程》及 其附件、修订及制定部分内部管理制度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海君实生物医药科技股份有限公司（以下简称"公司"）于 2025 年 8 月 26 日召开第四届董事会第十次会议，审议通过了《关于变更注册资本、取消监 事会、修订<公司章程>及其附件的议案》《关于修订及制定部分内部管理制度 的议案》，同日，公司召开第四届监事会第八次会议，审议通过了《关于取消监 事会、废止<监事会议事规则>的议案》。现将有关事项公告如下： 一、变更注册资本相关情况 2025 年 6 月 20 日，公司完成根据一般授权配售新 H 股，按每股 H 股 25.35 港元的配售价格向符合条件的承配人成功配售合计 41,000,000 股 H 股配售股份。 本次配售完成后，公司总股本由 985,689,871 股增加至 1,026,689,871 股，其中 A 股总股本为 ...

上海君实生物医药科技股份有限公司 2025 年度"提质增效重回报"行动方案的 半年度评估报告 为进一步履行社会责任，全方位推动公司经营的持续优化与升级，上海君实 生物医药科技股份有限公司（以下简称"公司"）结合自身发展战略和经营情况， 制定了《上海君实生物医药科技股份有限公司 2025 年度"提质增效重回报"行 动方案》（以下简称"2025 年行动方案"或"本方案"），详细情况参见公司已于 2025 年 3 月 28 日披露于上海证券交易所网站（www.sse.com.cn）的公告。2025 年上半年，公司切实履行并持续评估 2025 年行动方案的具体举措，现将 2025 年行动方案在 2025 年半年度（以下简称"报告期"）内的实施和效果评估情况报 告如下： 一、提升经营效率，加强合规建设，促进高质量发展 公司具备完整的从创新药物的发现和开发、在全球范围内的临床研究、大规 模生产到商业化的全产业链能力，旨在成为立足中国、布局全球的创新医药公司。 公司坚持质量为本、求真务实、诚信合规、追求卓越的企业价值观，致力于通过 源头创新以及合作开发等形式来研发 first-in-class（同类首创）或 best-in ...

Group 1 - The core viewpoint of the article highlights that Junshi Biosciences reported a revenue of 1.168 billion yuan for the first half of 2025, representing a year-on-year growth of 48.64% [1] - The net loss attributable to shareholders of the listed company was 413 million yuan, an improvement from a net loss of 645 million yuan in the same period last year [1] - Research and development expenses accounted for 60.39% of the revenue, which is a decrease of 9.12 percentage points compared to the previous year [1]

Market Overview - The Hong Kong stock market failed to maintain its strong performance from the previous day, with all three major indices experiencing a collective adjustment. The Hang Seng Index fell by 1.18% or 304.99 points, closing at 25,524.92 points, with a total trading volume of HKD 31.78 billion. The Hang Seng China Enterprises Index decreased by 1.07% to 9,148.66 points, while the Hang Seng Tech Index dropped by 0.74% to 5,782.24 points [1] Blue-Chip Stocks Performance - CSPC Pharmaceutical Group (01093) led the decline among blue-chip stocks, falling by 4.33% to HKD 10.38, with a trading volume of HKD 1.797 billion, contributing a loss of 6.04 points to the Hang Seng Index. Bank of America Securities reported a 14.3% year-on-year decline in total revenue for CSPC in Q2, with attributable net profit down 24% to RMB 1.1 billion. The firm revised its revenue forecasts for 2025 to 2027 down by 25%, 2%, and 11% respectively [2] Sector Highlights - Large technology stocks mostly declined, with Alibaba down 2.57% and Tencent down 0.81%. Gold stocks surged, with China Gold International rising over 10%. Apple is expected to initiate a three-year innovation cycle, boosting related stocks like Lens Technology, which rose over 5%. Gaming stocks and some new consumption concepts performed well, with Melco International Development up over 9% [3][5] Federal Reserve Insights - Federal Reserve Chairman Jerome Powell indicated rising downside risks in the U.S. labor market, suggesting a potential policy adjustment could be appropriate. This statement is seen as a strong signal for a possible interest rate cut as early as September. The market reacted positively, particularly for precious metals, with expectations for further increases in gold prices [4] Gaming Sector Performance - The gaming sector continued its upward trend, with Melco International Development rising 9.27% to HKD 5.54. According to JPMorgan, Macau's gaming revenue for the first 24 days of August reached MOP 17.65 billion, with a daily average of MOP 735 million, reflecting a 9% increase from the previous week [6] Pharmaceutical Sector Challenges - The pharmaceutical sector faced pressure, with several stocks declining. Notably, CStone Pharmaceuticals (09966) fell 6.74% to HKD 10.24. U.S. President Trump's announcement to drastically reduce drug prices could create significant challenges for the global pharmaceutical industry, presenting both opportunities and risks for Chinese biotech stocks [6] Notable Stock Movements - Double Ended Co. (06960) debuted with a 31.29% increase, closing at HKD 19.05. The company focuses on energy storage solutions in the data and communication sectors, with a projected market share of 11.1% by 2024 [7] - Kingsoft Holdings (03918) reached a new high, rising 17.94% to HKD 5.72, reporting a 16.76% year-on-year revenue increase to USD 342 million [8] - Angelalign Technology (06699) saw a 10.28% increase to HKD 75.1, with a 33.1% year-on-year revenue growth reported [9] - Meitu Inc. (01357) rose 7.9% to HKD 11.47 after being included in the MSCI China Index, with Morgan Stanley expressing confidence in its long-term growth potential [10] - Xintai Medical (02291) experienced a significant drop of 12.75% to HKD 23.96 following a major shareholder's sale of shares [11]

| 指数 | 最新 | 涨跌幅 | | --- | --- | --- | | 相生指数 | 25524.92 | -1.18% | | 国企指数 | 9148.66 | -1.07% | | 红筹指数 | 4343.85 | -1.02% | 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每经AI快讯：北京时间8月26日16:00，恒生指数收盘下跌304.99点，跌幅为1.18%，报收25524.92点；国 企指数收盘下跌99.34点，跌幅为1.07%，报收9148.66点；红筹指数收盘下跌44.65点，跌幅为1.02%，报 收4343.85点。南向资金当日净流入165.73亿港元。东方甄选跌超11%，蔚来、君实生物跌超6%，中兴 通讯跌近6%，碧桂园跌超5%；中国黄金国际涨超10%，灵宝黄金涨超9%。 （记者 胡玲） ...

Group 1 - The core viewpoint of the article highlights a significant decline in Hong Kong's biopharmaceutical stocks, with notable drops in several companies [2] Group 2 - Junshi Biosciences and Kelun Pharmaceutical both experienced declines exceeding 7% [2] - Innovent Biologics saw a drop of over 4% [2] - WuXi AppTec, Tigermed, and CanSino Biologics all fell by more than 3% [2]

Group 1 - The core viewpoint of the article highlights the overall poor performance of Hong Kong's biopharmaceutical stocks, with significant declines in major companies such as WuXi AppTec, Tigermed, and King’s Ray Biotech [1] - U.S. President Trump announced plans to reduce drug prices to 1/1400 to 1/1500 of current prices and to impose tariffs on pharmaceuticals, which could create volatility in the global pharmaceutical industry [1] - The Chinese biopharmaceutical sector faces both opportunities and challenges due to these developments, with potential short-term market fluctuations driven by uncertainty, particularly for businesses exposed to the U.S. market [1] Group 2 - In the long term, China's pharmaceutical industry may leverage its innovation and supply chain advantages to find new growth opportunities in the global pharmaceutical landscape, especially in areas like CDMO and internationalization of innovative drugs [1] - The article lists the latest prices and percentage changes for various biopharmaceutical stocks, indicating a general downward trend across the sector [1]

Core Viewpoint - The report highlights the changes in the Hong Kong Stock Connect holdings, indicating significant increases and decreases in ownership percentages for various companies, which may signal potential investment opportunities or shifts in market sentiment. Group 1: Increased Holdings - Shandong Molong (00568) saw the largest increase in Hong Kong Stock Connect holdings, rising by 3.41% to a total holding of 58.38% [2] - ZTE Corporation (00763) experienced a 2.52% increase, bringing its holding to 54.86% [2] - Lens Technology (06613) increased by 2.22%, with a current holding of 11.01% [2] - Other notable increases include Southern Hang Seng Technology (03033) at +2.08% (60.66%) and Beijing Jingcheng Machinery Electric Company (00187) at +1.35% (49.54%) [2] Group 2: Decreased Holdings - Hang Seng China Enterprises (02828) had the largest decrease, down by 2.31% to 1.02% [2] - The Tracker Fund of Hong Kong (02800) decreased by 0.74%, now holding 1.87% [2] - Li Jin Technology (00558) saw a reduction of 0.69%, with a holding of 14.36% [2] - Other significant decreases include Ping An Good Doctor (01833) at -0.65% (19.25%) and Beijing North Star Company (00588) at -0.59% (41.42%) [2] Group 3: Five-Day Changes - Over the last five trading days, ZTE Corporation (00763) had the highest increase in holdings at +7.26% (54.86%) [3] - Longpan Technology (02465) increased by 6.03% to 51.76% [3] - Tongyuan Kang Pharmaceutical-B (02410) rose by 5.38%, now at 14.68% [3] - Significant decreases included Dongyang Sunshine Pharmaceutical (06887) at -3.85% (44.05%) and Zhejiang Shibao (01057) at -2.73% (55.74%) [3] Group 4: Twenty-Day Changes - Longfei Optical Fiber and Cable (06869) had the largest increase over twenty days at +22.04% (56.07%) [4] - Meizhong Jiahe (02453) increased by 12.55% to 37.75% [4] - Other notable increases include Yimai Sunshine (02522) at +11.66% (40.40%) and Kanglong Chemical (03759) at +9.51% (59.33%) [4] - Decreases over twenty days included Chongqing Steel (01053) at -5.91% (32.47%) and Dongfang Electric (01072) at -5.60% (37.80%) [4]

Group 1 - The article highlights the top three companies with the highest AH premium rates as Northeast Electric (00042) at 743.75%, Hongye Futures (03678) at 241.98%, and Andeli Juice (02218) at 236.37% [1] - The bottom three companies with the lowest AH premium rates include Ningde Times (03750) at -16.43%, Heng Rui Medicine (01276) at 1.82%, and Midea Group (00300) at 4.90% [1] - The article provides a detailed table of the top ten and bottom ten AH stocks based on premium rates and deviation values, indicating significant disparities in market valuations between H-shares and A-shares [1][2] Group 2 - The deviation values for the top three companies are Andeli Juice (02218) at 32.29%, Jinli Permanent Magnet (06680) at 22.19%, and Beijing Machinery (00187) at 20.80% [1] - The companies with the lowest deviation values include BYD Company (01211) at -98.36%, Northeast Electric (00042) at -64.84%, and Longpan Technology (02465) at -51.92% [1][2] - The article emphasizes that the deviation value represents the difference between the current premium rate and the average premium rate over the past 30 days, providing insights into market trends [2]